Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 20-30
Closed Access | Times Cited: 326

Showing 1-25 of 326 citing articles:

Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 271
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial
Ornella Verrastro, Simona Panunzi, Lidia Castagneto‐Gissey, et al.
The Lancet (2023) Vol. 401, Iss. 10390, pp. 1786-1797
Open Access | Times Cited: 170
Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019
Bryan Chong, Jayanth Jayabaskaran, Gwyneth Kong, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101850-101850
Open Access | Times Cited: 163
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
Elina Cho, C. Ang, Jingxuan Quek, et al.
Gut (2023) Vol. 72, Iss. 11, pp. 2138-2148
Closed Access | Times Cited: 111
Excess body weight: Novel insights into its roles in obesity comorbidities
Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 16-27
Open Access | Times Cited: 103
Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Gres Karim, Meena B. Bansal
touchREVIEWS in Endocrinology (2023) Vol. 19, Iss. 1, pp. 60-60
Open Access | Times Cited: 66
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies
Kai En Chan, Elden Yen Hng Ong, Charlotte Hui Chung, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 3, pp. 488-498.e14
Closed Access | Times Cited: 49
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease
Rohit Loomba, Vincent Wai‐Sun Wong
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 2, pp. 150-156
Open Access | Times Cited: 48
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Lianzhou Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 40
Updated mechanisms of MASLD pathogenesis
Yuxuan Li, Peipei Yang, Jialu Ye, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 33
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti, et al.
Ultrasound in Medicine & Biology (2024) Vol. 50, Iss. 8, pp. 1071-1087
Closed Access | Times Cited: 31
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 29
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
Preethi Chandrasekaran, Ralf Weiskirchen
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1109-1109
Open Access | Times Cited: 26
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 26
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 25
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 12, pp. 834-851
Closed Access | Times Cited: 20
Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Camille Lupiañez-Merly, Saam Dilmaghani, Kia Vosoughi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 4, pp. 475-491
Closed Access | Times Cited: 18
Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System
Antonis A. Manolis, Theodora A. Manolis, Apostolos Vouliotis, et al.
Trends in Cardiovascular Medicine (2025)
Closed Access | Times Cited: 4
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Laurent Castéra, William Alazawi, Elisabetta Bugianesi, et al.
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 1
Effects of Sympathetic Denervation in Metabolism Regulation: A Novel Approach for the Treatment of MASLD?
Kyriakos Dimitriadis, Panagιotis Iliakis, Angeliki Vakka, et al.
Cardiology in Review (2025)
Closed Access | Times Cited: 1
Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management
Daniel Simancas‐Racines, Giuseppe Annunziata, Ludovica Verde, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Carbon tetrachloride does not promote hepatic fibrosis in ob/ob mice via downregulation of lipocalin-2 protein
Hyun Joo Shin, Kyung Eun Kim, Hyeong Seok An, et al.
Redox Biology (2025) Vol. 80, pp. 103506-103506
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top